Thanou M. – TechConnect Briefs

Novel Cleavable PEGylated Liposomes for Enzyme Triggerable Release of Nucleic Acid in Tumours

Yingyuad P., Miller A., Thanou M., Imperial College Genetic Therapies Centre, UK

We have developed a dePEGylation approach based on the activity of the proteolytic enzymes that are associated with tumour cells. The elevated enzyme activity facilitates the extravasation of the cells by degrading the extracellular matrix [...]

Enhanced fluid transport through carbon nanopipes

Whitby M., Cagnon L., Thanou M., Quirke N., Imperial College, UK

Experimental measurement of fluid flow and diffusion through nanoscale channels is important both for determining how classical theories of fluid dynamics apply at very small length scales and with a view to constructing practical nanofluidic [...]

Carbon Nanopipes dispersions in aqueous solutions and effects on cell viability

Whitby M., Lin J., Quirke N., Thanou M., Imperial College London, UK

The development of carbon nanomaterials for biomedical applications appears highly attractive due to their nanoscale properties although their biological profile is still in doubt. Herewith, we report that the amorphous vs crystalline character of carbon [...]

How much advantage do Nanoscale Phenomena afford for Pulmonary Delivery?

Walji N., Thanou M., Quirke N., Imperial College London, UK

Although claims of improved performance due to nanoscale phenomena are made on a daily basis, exactly how much advantage can be afforded by nanotechnology for specific medical applications is quantitatively unknown. It is generally suggested [...]

Organisation of peptide ligands on the surface of gene vectors

Wang M., Miller A.D., Thanou M., Imperial College London, UK

Through the considerate organisation of surface ligands, we have developed a lipid-based vector for the targeted delivery to cancer cells. Our ligand is a short peptide with high affinity for the Urokinase Plasminogen Activator receptor [...]

Multilayered ABCD Nanoparticles for siRNA delivery

Thanou M., Miller A., Imperial College London, UK

RNAi therapeutics represent a method to treat human diseases by addressing targets that are not possible to be addressed with conventional medicines. In our Centre we design nanosized systems for siRNA delivery that consist of [...]